Metsera (MTSR), which is developing ultra-long-acting drugs for the treatment of obesity, has set terms for an upsized $275M initial public offering. Read more here.

Weight-loss drug developer Metsera is targeting an up to $1.78 billion valuation in its initial public offering, the ARCH Venture Partners-backed biotech company said on Monday. New York City-based ...

(Reuters) -Metsera, which is developing weight-loss drugs, said on Monday it is seeking a valuation of up to $1.78 billion in ...

Fortuna Investments CEO Justus Parmar expects to see “a new vintage of space companies that hit the market” in 2025.

WTI Crude Oil ( CL1:COM) is overbought, and investors should sell into $80 resistance. Investors should “sell, baby, sell,” said Rich Ross, head of Technical Analysis at Evercore ISI, in a note.

Karman Space and Defense ("Karman" or the "Company"), a company specializing in the upfront design, testing, manufacturing, ...